The Clinical Pipeline - a new column from Nature Medicine

This week Nature Medicine published the third in a new fortnightly column called The Clinical Pipeline.
Our goal is to further strengthen the journal's coverage of translational and clinical research, from bench to bedside, and so each column will analyse a recent clinical trial announcement, preprint, or journal publication (with all the caveats that apply to non-peer reviewed research!)
Thiago Carvalho is writing these articles for us, as an experienced Nature Medicine freelancer and author of our COVID Research in Brief articles during the pandemic.
Thiago's first column covered BioNTech’s new combination mRNA / CAR-T cancer vaccine; the second column discussed the unknown efficacy of the antiviral, tecovirimat, against monkeypox; and today's column covers how the FDA are using biomarker data in the approval of new drugs for amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease.
This is something of an experiment for the journal, so please let us know if you found them interesting and/or useful - or any other feedback!
Follow the Topic
-
Nature Medicine
This journal encompasses original research ranging from new concepts in human biology and disease pathogenesis to new therapeutic modalities and drug development, to all phases of clinical work, as well as innovative technologies aimed at improving human health.
Related Collections
With collections, you can get published faster and increase your visibility.
Stem cell-derived therapies
Publishing Model: Hybrid
Deadline: Jun 26, 2025
Please sign in or register for FREE
If you are a registered user on Research Communities by Springer Nature, please sign in